Archive for July, 2010

CORT Implements Electronic Health Records

July 14, 2010

CORT is pleased to announce our implementation of the OmniMD electronic health record system.  Our implementation will be occurring over the next 4-8 weeks.   This system was selected after a review of over 30 systems.  This web-based system will provide access to patient records for our physicians and providers from any point of care.  The system is full-featured, with electronic medication prescribing, encounter documentation, chemotherapy documentation, and lab integration.  In our next phase of integration, we will be opening our Patient Portal, which will allow patients to go online through a secure password-protected portal to view their records, lab, request appointments and prescriptions, and send messages to clinic providers.  We believe this will facilitate better care delivery and rapid communication with patients and referring physicians.

CORT Moves Focus to Personalized Cancer Therapy, Away from Research Trials

July 14, 2010

With regrets to past, present, and future patients and referring physicians, CORT has terminated participation in many research trials over the past few months. As many of you may have followed this blog site, or linked to it from others, you might have noticed there has been a decline in our acceptance of and participation in new trial program offerings. Providing research opportunities, in addition to standard therapy options has been an expensive endeavor, with high overhead costs for research personnel and facilities. CORT is not and has not been supported by governmental grants. Trials funded by both National Caner Institute and private Pharma sponsors have been woefully underfunded, not meeting costs of conducting these trials. I will continue to support research participation even if it does not occur through my practice directly, but by my referral of patients to participate at other sites.

The long term commitment that CORT has had to providing access to innovative and high-quality cancer drug therapy continues without interruption. As can be seen in the history of our many posts, CORT has years of experience in providing cutting-edge therapies. That experience spills over to all therapy selections (not just study treatment), management of treatment side effects, and probably most importantly, in the commitment to comprehensive planning of individualized treatment approaches for each patient.  As treatment evolves to therapy selection based on genetic and molecular profiling of individual tumor specimens, CORT will remain a leader.

Future posts will focus on some of the fantastic new developments occurring with ever accelerating speed in our field.  My interest is how these developments can be translated rapidly to the patients, and how selection of the therapy can be tailored individually whenever possible.